Floatz logo

Bexarotene

Cutaneous T-cell Lymphoma

Case Comprehensive Cancer CenterSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
89/ 100

Competitive context

61 Active assets in the Cutaneous T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB
Inno-206
Falo, Louis, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

Bexarotene is also rated in:

primary cutaneous anaplastic large cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
mycosis fungoidesDormant
B
Indicative ·
63 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →